Back to results
US 8,673,873 B1Granted
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
AssigneeAlcon Research, Ltd.
InventorsJohn M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
Claims6
A method of attenuating expression of a PDE4 mRNA in an eye of a subject, the method comprising:
- administering to an eye of the subject a composition comprising an effective amount of interfering RNA and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense strand that is 19 nucleotides in length and is the corresponding mRNA sequence of SEQ ID NO:
- 108 or SEQ ID NO:
- 109, wherein the expression of the PDE4 mRNA is attenuated thereby.
Dependencies are inferred from the claim text.